Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

Table 2

Visual and anatomic outcomes following bevacizumab injection.

	PRN group (𝑛=69)	Three monthly initial dose group (𝑛=26)	𝑃^∗
Visual improvement at month 6 (%)	44 (63.8%)	17 (65.4%)	0.89
Complete resolution at month 6 (%)	40 (58.0%)	13 (50.0%)	0.50
Recurrence over 6-month period (%)	42 (60.9%)	12 (46.2%)	0.20
Absorption of retinal hemorrhage^†
Month 3, %	9.3±10.4	16.2±10.5	0.027
Month 6, %	15.1±13.9	18.3±13.1	0.41
Change of nonperfusion area^†
Month 3, %	−0.1±2.0^‡	−0.8±1.8^‡	0.46
Month 6, %	0.4±3.3^‡	−0.3±3.26^‡	0.50

^∗𝑃 values were obtained by Student’s 𝑡-test for continuous variables and chi-square test for dichotomous variables.
^†Percentages were calculated by dividing the area of hemorrhage absorption or change in nonperfusion areas by the area of the circle with a radius of 3600 𝜇m.
^‡Negative numbers indicate the decrease in the area of nonperfusion during the time period.
Boldface indicates statistical significance (𝑃<0.05).